What's Happening?
Corcept Therapeutics has received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for treating adults with platinum-resistant ovarian cancer. This approval is based on the ROSELLA trial, which showed a 35% reduction in the risk
of death and a 30% reduction in disease progression for patients treated with the combination therapy. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist for this condition, offering a new treatment option for patients who have limited alternatives.
Why It's Important?
The approval of Lifyorli marks a significant advancement in the treatment of platinum-resistant ovarian cancer, a condition with few effective treatment options. This development provides a new standard-of-care for patients, potentially improving survival rates and quality of life. The approval also highlights the role of cortisol modulation in oncology, opening new avenues for research and treatment in other cancer types. For Corcept, this approval could enhance its market position and drive future growth in the oncology sector.
What's Next?
Corcept plans to present complete results from the ROSELLA trial at the upcoming Society of Gynecologic Oncology meeting. The company is also exploring further development of relacorilant in other cancers, including endometrial, cervical, pancreatic, and prostate cancers. Additionally, Corcept is committed to ensuring timely patient access to Lifyorli, which may involve collaborations with healthcare providers and patient advocacy groups to facilitate distribution and support.
